Highlights
- Market Cap
- $1.31B
- Enterprise Value
- $730.16M
- EPS (TTM)
- -$1.20
- Total Revenue (TTM)
- $42.73M
- Gross Profit (TTM)
- $21.12M
- EBITDA (TTM)
- -$206.29M
- Year Range
- $5.02 - $21.73
- Target Price
- $32.00
- ROA (TTM)
- -862.90%
- ROE (TTM)
- -39.43%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Wave Life Sciences Ltd., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Wave Life Sciences Ltd. (WVE) has returned -57.35% so far this year and -10.27% over the past 12 months. Over the last ten years, WVE has returned -6.17% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Wave Life Sciences Ltd.
- 1D
- 9.52%
- 1M
- -47.95%
- YTD
- -57.35%
- 6M
- -0.96%
- 1Y
- -10.27%
- 3Y*
- 18.75%
- 5Y*
- 3.55%
- 10Y*
- -6.17%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Nov 11, 2015, WVE's average daily return is +0.15%, while the average monthly return is +2.69%. At this rate, your investment would double in approximately 2.2 years.
Historically, 46% of months were positive and 54% were negative. The best month was Jun 2022 with a return of +132.1%, while the worst month was Dec 2019 at -75.8%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, WVE closed higher 49% of trading days. The best single day was Dec 8, 2025 with a return of +147.3%, while the worst single day was Dec 16, 2019 at -55.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -23.88% | 7.65% | -47.95% | -57.35% | |||||||||
| 2025 | -6.47% | -8.64% | -23.56% | -4.46% | -22.15% | 8.15% | 24.62% | 18.52% | -23.75% | 23.50% | -14.16% | 119.07% | 37.43% |
| 2024 | -14.46% | 11.34% | 28.27% | -20.10% | 25.35% | -19.26% | 32.46% | -13.16% | 42.86% | 67.20% | 10.14% | -18.08% | 144.95% |
| 2023 | -29.57% | -14.81% | 3.10% | -7.85% | -0.75% | -8.08% | 20.05% | -0.46% | 32.18% | -6.43% | -1.30% | -4.90% | -27.86% |
| 2022 | -30.25% | 12.10% | -18.53% | -2.50% | -28.21% | 132.14% | -21.85% | 16.93% | 21.55% | 32.69% | -11.48% | 65.09% | 122.93% |
| 2021 | 29.22% | -7.47% | -40.38% | 9.63% | 11.22% | -2.63% | -17.27% | 14.88% | -22.59% | -6.33% | -15.03% | -19.49% | -60.10% |
Benchmark Metrics
Wave Life Sciences Ltd. has an annualized alpha of 25.50%, beta of 1.16, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since November 12, 2015.
- This stock tended to rise when S&P 500 Index fell (downside capture of -75.89%), but participation in market rallies was also limited (-43.78%) — a profile typical of counter-cyclical assets.
- R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 25.50%
- Beta
- 1.16
- R²
- 0.04
- Upside Capture
- -43.78%
- Downside Capture
- -75.89%
Return for Risk
Risk / Return Rank
WVE ranks 46 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Wave Life Sciences Ltd. (WVE) and compare them to a chosen benchmark (S&P 500 Index).
| WVE | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.06 | 0.90 | -0.96 |
Sortino ratioReturn per unit of downside risk | 1.26 | 1.39 | -0.13 |
Omega ratioGain probability vs. loss probability | 1.20 | 1.21 | -0.01 |
Calmar ratioReturn relative to maximum drawdown | -0.22 | 1.40 | -1.62 |
Martin ratioReturn relative to average drawdown | -0.60 | 6.61 | -7.20 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore WVE risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Wave Life Sciences Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Wave Life Sciences Ltd. was 97.77%, occurring on May 13, 2022. The portfolio has not yet recovered.
The current Wave Life Sciences Ltd. drawdown is 86.87%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.77% | Sep 25, 2018 | 916 | May 13, 2022 | — | — | — |
| -61.44% | Nov 28, 2016 | 160 | Jul 18, 2017 | 130 | Jan 23, 2018 | 290 |
| -50.97% | Dec 23, 2015 | 36 | Feb 16, 2016 | 21 | Mar 16, 2016 | 57 |
| -38.12% | Feb 20, 2018 | 88 | Jun 25, 2018 | 63 | Sep 24, 2018 | 151 |
| -36.57% | Mar 17, 2016 | 13 | Apr 5, 2016 | 53 | Jun 20, 2016 | 66 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Wave Life Sciences Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Wave Life Sciences Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for WVE relative to other companies in the Biotechnology industry. Currently, WVE has a P/S ratio of 29.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for WVE in comparison with other companies in the Biotechnology industry. Currently, WVE has a P/B value of 2.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |